Recruiting Endometrial Cancer Studies in Little Rock
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemot...
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (pac...
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer....
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) o...
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer...
About Endometrial Cancer Clinical Trials in Little Rock
Endometrial cancer begins in the lining of the uterus and is the most common gynecologic cancer. It is often detected early due to abnormal bleeding symptoms. Treatment typically involves surgery, with radiation, chemotherapy, or hormone therapy for advanced cases.
There are currently 6 endometrial cancer clinical trials recruiting participants in Little Rock, AR. These studies are seeking a combined 2,202 participants. Research is being sponsored by Gilead Sciences, AstraZeneca, National Cancer Institute (NCI) and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Endometrial Cancer Clinical Trials in Little Rock — FAQ
Are there endometrial cancer clinical trials in Little Rock?
Yes, there are 6 endometrial cancer clinical trials currently recruiting in Little Rock, AR. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Little Rock?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.
Are clinical trials in Little Rock free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.
What endometrial cancer treatments are being tested?
The 6 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for endometrial cancer.
Data updated March 2, 2026 from ClinicalTrials.gov